News
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the U.S. FDA has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable,...
News
Llama nanobodies could be a powerful weapon against COVID-19
The researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat...
Drug Research
Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration
Oxford Biomedica plc , a leading gene and cell therapy group and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, announced that they have entered into a discovery collaboration to develop next-generation CAR-T...
News
CDMOs benefit from COVID-19 impacts but mega-cap pharma innovation slowing outsourcing according to CPhI Annual Report
The global contact services sector is benefiting from a switch towards COVID-19 manufacturing (vaccine and therapy) and clinical stage contracts, but mega-cap innovator drug approvals are reducing commercial demand according to the CPhI Annual Report contract services findings.
Adam Bradbury,...
Clinical Trials
Pfizer Announces Positive Phase 3 Study Results for XELJANZ in Ankylosing Spondylitis
Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofacitinib is not currently approved by the U.S. Food and Drug Administration (FDA) for...
News
Lonza Celebrates the Grand Opening of a New Facility for ADC Payload Manufacturing
Lonza, a specialty CDMO partner to the biopharma industry, today inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp (CH) site. This first manufacturing suite handles compounds with occupational exposure levels...
News
ACG Invests in Mumbai-Based start-up contract research organization IQGEN-X
Supplier of integrated pharmaceutical manufacturing solutions, ACG, has revealed in a Nov. 3, 2020 press release, that it has acquired a significant stake in IQGEN-X, a Mumbai-based start-up contract research organization (CRO).
The investment supports ACG’s augmentation into R&D and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















